top of page


Individualized Dosing of Therapeutic Monoclonal Antibodies: A Changing Treatment Paradigm?

A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab in Relapse Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Identification of Peptide Mimotope Ligands for Natalizumab

A General Process for the Development of Peptide-Based Immunoassays for Monoclonal Antibodies

bottom of page